CN1915222A - 一种脂质体组合物及其制备方法 - Google Patents
一种脂质体组合物及其制备方法 Download PDFInfo
- Publication number
- CN1915222A CN1915222A CN 200610127394 CN200610127394A CN1915222A CN 1915222 A CN1915222 A CN 1915222A CN 200610127394 CN200610127394 CN 200610127394 CN 200610127394 A CN200610127394 A CN 200610127394A CN 1915222 A CN1915222 A CN 1915222A
- Authority
- CN
- China
- Prior art keywords
- aspirin
- group
- mixture
- alprostadil
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 239000002502 liposome Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 21
- 239000003814 drug Substances 0.000 claims abstract description 84
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims abstract description 66
- 229960000711 alprostadil Drugs 0.000 claims abstract description 66
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims abstract description 65
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 60
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 42
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 20
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 20
- 239000004471 Glycine Substances 0.000 claims abstract description 13
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 7
- 206010022437 insomnia Diseases 0.000 claims abstract description 7
- 229940067606 lecithin Drugs 0.000 claims abstract description 7
- 239000000787 lecithin Substances 0.000 claims abstract description 7
- 235000010445 lecithin Nutrition 0.000 claims abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 6
- 208000028867 ischemia Diseases 0.000 claims abstract description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 235000006708 antioxidants Nutrition 0.000 claims description 19
- JJBCTCGUOQYZHK-ZSCHJXSPSA-N 2-acetyloxybenzoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O JJBCTCGUOQYZHK-ZSCHJXSPSA-N 0.000 claims description 18
- -1 Polyethylene Polymers 0.000 claims description 14
- 239000004698 Polyethylene Substances 0.000 claims description 13
- 229920000573 polyethylene Polymers 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 229930003268 Vitamin C Natural products 0.000 claims description 12
- 239000000823 artificial membrane Substances 0.000 claims description 12
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 12
- 235000019154 vitamin C Nutrition 0.000 claims description 12
- 239000011718 vitamin C Substances 0.000 claims description 12
- 238000009210 therapy by ultrasound Methods 0.000 claims description 11
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims description 8
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims description 8
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 8
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 8
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 8
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 8
- 229960002733 gamolenic acid Drugs 0.000 claims description 8
- 102000002322 Egg Proteins Human genes 0.000 claims description 6
- 108010000912 Egg Proteins Proteins 0.000 claims description 6
- 241000287828 Gallus gallus Species 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-M argininate Chemical compound [O-]C(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-M 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 238000005374 membrane filtration Methods 0.000 claims description 6
- 210000004681 ovum Anatomy 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims 2
- 238000004659 sterilization and disinfection Methods 0.000 claims 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 69
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 229930182558 Sterol Natural products 0.000 abstract 1
- 210000002969 egg yolk Anatomy 0.000 abstract 1
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 30
- 239000007924 injection Substances 0.000 description 20
- 238000002347 injection Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 229940078241 aspirin 250 mg Drugs 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 206010020772 Hypertension Diseases 0.000 description 12
- 229940097766 aspirin 200 mg Drugs 0.000 description 12
- 229940085421 aspirin 500 mg Drugs 0.000 description 12
- 230000001631 hypertensive effect Effects 0.000 description 12
- 230000002269 spontaneous effect Effects 0.000 description 12
- 206010002660 Anoxia Diseases 0.000 description 8
- 241000976983 Anoxia Species 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 206010021143 Hypoxia Diseases 0.000 description 8
- 230000007953 anoxia Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 201000007270 liver cancer Diseases 0.000 description 8
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000009834 vaporization Methods 0.000 description 5
- 230000008016 vaporization Effects 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 229940084983 cyclophosphamide 50 mg Drugs 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
对照药物d组 | 1430 | 1150 | 15 | 15 | 17 |
对照药物a组 | 1150 | 1290 | 15 | 9 | 1 |
对照药物b组 | 1130 | 1121 | 15 | 2 | 20 |
对照药物c组 | 1290 | 1350 | 15 | 20 | 25 |
对照药物d组 | 1430 | 1150 | 15 | 15 | 17 |
本发明药物a组 | 740 | 710 | 5 | 2 | 2 |
本发明药物b组 | 800 | 810 | 5 | 1 | 1 |
本发明药物c组 | 860 | 847 | 10 | 1 | 1 |
对照药物a组 | 1160 | 1296 | 15 | 9 | 1 |
对照药物b组 | 1130 | 1121 | 15 | 2 | 20 |
对照药物c组 | 1290 | 1350 | 15 | 20 | 25 |
对照药物d组 | 1430 | 1150 | 15 | 15 | 17 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101273942A CN1915222B (zh) | 2006-09-18 | 2006-09-18 | 一种脂质体组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101273942A CN1915222B (zh) | 2006-09-18 | 2006-09-18 | 一种脂质体组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1915222A true CN1915222A (zh) | 2007-02-21 |
CN1915222B CN1915222B (zh) | 2010-08-04 |
Family
ID=37736382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101273942A Expired - Fee Related CN1915222B (zh) | 2006-09-18 | 2006-09-18 | 一种脂质体组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1915222B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITCA20080017A1 (it) * | 2008-07-31 | 2010-02-01 | Giuseppe Brotzu | Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari. |
CN101019872B (zh) * | 2007-03-08 | 2010-12-01 | 蔡海德 | 抗病毒纳米脂质体药物及其制备方法 |
CN101327190B (zh) * | 2008-07-29 | 2011-04-27 | 北京大学 | 一种供注射用的抗肿瘤长循环靶向脂质体 |
CN102247579A (zh) * | 2010-07-29 | 2011-11-23 | 邓学峰 | 醒脑静脂质体组合药物配方及制备方法和用途 |
CN102274184A (zh) * | 2011-07-28 | 2011-12-14 | 蔡海德 | 前列地尔脂质体组合药物及工业制备和质量控制和用途 |
CN103816529A (zh) * | 2014-03-20 | 2014-05-28 | 蔡欣 | 治疗多种重病缠身的药物组合及其制备和用途 |
CN112587560A (zh) * | 2019-09-17 | 2021-04-02 | 蔡海德 | 一种中药为主的药物组合物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102204920B (zh) * | 2011-03-18 | 2013-03-20 | 海南本创医药科技有限公司 | 阿司匹林钠普伐他汀钠药物组合物固体制剂 |
CN110101719A (zh) * | 2018-02-01 | 2019-08-09 | 蔡海德 | 一种新型皮肤消毒剂 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990044445A (ko) * | 1995-09-13 | 1999-06-25 | 니뽄 신야쿠 가부시키가이샤 | Pge1 함유 동결건조 제제 및 그 제법 |
CN1398592A (zh) * | 2002-06-19 | 2003-02-26 | 蔡海德 | 治疗肿瘤、心脑血管疾病的药物组合物 |
CN1314444C (zh) * | 2003-03-20 | 2007-05-09 | 蔡海德 | 一种治疗糠尿病及其并发症和病毒性肝炎的组合药物及其制备方法 |
-
2006
- 2006-09-18 CN CN2006101273942A patent/CN1915222B/zh not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101019872B (zh) * | 2007-03-08 | 2010-12-01 | 蔡海德 | 抗病毒纳米脂质体药物及其制备方法 |
CN101327190B (zh) * | 2008-07-29 | 2011-04-27 | 北京大学 | 一种供注射用的抗肿瘤长循环靶向脂质体 |
ITCA20080017A1 (it) * | 2008-07-31 | 2010-02-01 | Giuseppe Brotzu | Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari. |
CN102247579A (zh) * | 2010-07-29 | 2011-11-23 | 邓学峰 | 醒脑静脂质体组合药物配方及制备方法和用途 |
CN103768020A (zh) * | 2010-07-29 | 2014-05-07 | 蔡海德 | 复方紫杉醇脂质体组合药物及其大工业化生产工艺和用途 |
CN104323993A (zh) * | 2010-07-29 | 2015-02-04 | 湖南康都制药有限公司 | 盐酸昂丹司琼脂质体组合药物及其大工业化生产工艺和用途 |
CN104323994A (zh) * | 2010-07-29 | 2015-02-04 | 湖南康都制药有限公司 | 硝普钠脂质体组合药物及其大工业化生产工艺和用途 |
CN102274184A (zh) * | 2011-07-28 | 2011-12-14 | 蔡海德 | 前列地尔脂质体组合药物及工业制备和质量控制和用途 |
CN102274184B (zh) * | 2011-07-28 | 2013-05-08 | 蔡海德 | 前列地尔脂质体组合药物及工业制备和质量控制和用途 |
CN103816529A (zh) * | 2014-03-20 | 2014-05-28 | 蔡欣 | 治疗多种重病缠身的药物组合及其制备和用途 |
CN112587560A (zh) * | 2019-09-17 | 2021-04-02 | 蔡海德 | 一种中药为主的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN1915222B (zh) | 2010-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1915222A (zh) | 一种脂质体组合物及其制备方法 | |
CN1279900C (zh) | 用于睡眠障碍的加巴喷丁类似物 | |
CN101036633A (zh) | 一种奥美拉唑肠溶微丸胶囊及其制备方法 | |
CN101066251A (zh) | 一种质子泵抑制剂分散片 | |
CN1131420A (zh) | 无水结晶霉酚酸2-(4-吗啉代)乙酯(mycophenolate mofetil)及其静脉用制剂 | |
CN1840177A (zh) | 胸腺肽α1注射液及其制备方法 | |
CN1159004C (zh) | 具有高含量n-乙酰半胱氨酸的可吞咽片剂 | |
CN1165295C (zh) | 倍他司汀的控释组合物 | |
CN1482118A (zh) | 新颖的5-羟基-3-羧酸酯吲哚类衍生物及其制备方法 | |
CN101036642A (zh) | 银杏内酯b纳米脂质体药物及其制备方法 | |
CN101058566A (zh) | 桂哌齐特的新的药用盐及其制备方法 | |
CN1857288A (zh) | 一种复方甘草酸及其盐的缓释制剂及其制备方法 | |
CN1087171C (zh) | 适合中国人的多种维生素和矿物质/微量元素复合制剂 | |
CN1861064A (zh) | 一种含有薁磺酸钠与l-谷氨酰胺水溶性前体药物的组合物 | |
CN1679802A (zh) | 一种壮腰健肾制剂和制备方法 | |
CN101058567A (zh) | 桂哌齐特的新的药学上可接受的盐 | |
CN1208057C (zh) | 复方莪术油制剂及其制备方法 | |
CN1887875A (zh) | 哒嗪胺衍生物及其用于制备小rna病毒抑制剂的用途 | |
CN100335059C (zh) | 一种药物组合物及其用途 | |
CN1493289A (zh) | 羟喜树碱乳剂及其制备方法 | |
CN101058565A (zh) | 稳定的桂哌齐特水溶性盐 | |
CN1212842C (zh) | 美他多辛咀嚼片及其制备方法 | |
CN1887285A (zh) | 一种复方药物组合物及其制备方法及用途 | |
CN1089092C (zh) | 一种促分化抑增殖抗癌药二萜类化合物及其制备方法和用途 | |
CN1733116A (zh) | 治疗高血压症的药物制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU ZHONGDE PHARMACEUTICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: CAI HAIDE Effective date: 20120524 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120524 Address after: 330009, room 11, 201 Bai Yi, Xiangshan South Road, Jiangxi, Nanchang Patentee after: Jiangsu Zhong Yi medical science and Technology Co Ltd Address before: 330009, room 11, 201 Bai Yi, Xiangshan South Road, Nanchang, Jiangxi, Xihu District Patentee before: Cai Haide |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100804 Termination date: 20150918 |
|
EXPY | Termination of patent right or utility model |